Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The effects of Bleomycin A5 on infantile maxillofacial haemangioma | Luo and Zhao Head Face Medicine 2011 7 11 http content 7 1 11 HEAD FACE MEDICINE RESEARCH Open Access The effects of Bleomycin A5 on infantile maxillofacial haemangioma Quan-feng Luo and Fu-yun Zhao Abstract Objective To examine the effects of bleomycin A5 on infantile maxillofacial haemangiomas. Methods Bleomycin A5 was given by multiple intralesinoal injections and the dosage was given according to the age of the patient and size of the lesion. Parts of patients were accompanied by prednisone treatment 2-5 mg kg po QOD. Results All the haemangiomas involuted completely after treated with bloemycin A5 with better recovery of skin color and less scar forming in small haemangiomas. Conclusion Infantile haemangioma could be effectively treated with bleomycin A5 without serious side effects. Introduction Infantile hemangiomas are the most common tumor of infancy which are benign vascular proliferations composed of densely packed capillaries with endothelial cells and pericytes expanding in a lobular pattern. In contrast to vascular malformations infantile hemangiomas are usually absent or inconspicuous at birth and are characterized by a remarkably rapid postnatal proliferation and slow spontaneous involution. Although infantile haemangiomas can involute spontaneously it is still difficult to predict the progression of some infantile haemangioma even small lesions may result in major aesthetic handicap at certain sites especially for the big infantile haemangiomas 4 cm as it may develope to the extant of maxillofacial deformity and follow with complications usually bleeding ulceration or obstruction . Therefore some clinicians suggest that interfering in infantile haemangioma should be at the early stage 1-3 . Conservative therapies for infantile haemangiomas include pharmacotherapy laser therapy and consulting doctors regularly. Bleomycin BLM also known as Blenoxane was first isolated as a Cu2 -containing glycooligopeptide antibiotic from the .
